皮质发育障碍模型的建立及其致痫敏感性的研究

目的:建立皮质发育障碍模型,探讨皮质发育障碍模型的敏感性。方法:在SD大鼠孕17d腹腔注入1,3-二氯乙烯-亚硝基脲(BCNU)制作皮质发育障碍模型;Nissl染色观察P60d仔鼠病理变化;选取P60d雄性仔鼠,腹腔注射氯化锂-毛果芸香碱,分别比较两组大鼠癫发生的潜伏期、持续状态时间和死亡率。结果:同龄仔鼠脑组织湿重实验组比对照组显著减轻(P<0.01);Nissl染色显示皮质变薄、皮质层次紊乱、海马区域异位细胞异常聚集;有皮质发育障碍的仔鼠注射氯化锂-毛果芸香碱后,癫发生的潜伏期显著缩短(P<0.01),癫持续状态时间延长(P<0.01),死亡率显著升高(P<0.05)。结论:BCNU致皮质发育障碍模型具有癫易感性。     

临床Ⅲ°烧伤创面病人43例分析

分析４３例烧伤初期Ⅱ°创面演变为临床Ⅲ°烧伤创面的病人资料，发现演变多发生在伤后第１～２１天，发生的原因主要与清创、休克及并发症有关。因此，除进一步减少创面损伤外，应注意提高病人的机体抵抗力，处理好饶伤初期Ⅱ°创面。     

类保幼激素对三带喙库蚊幼期发育的影响

本文报告用亚致死剂量的 S—31183(类保幼激素)处理三带喙库蚊幼虫对其发育影响的研究,结果表明处理后蛹期死亡率明显高于幼虫期,并且与剂量大小有关。S—31183处理幼虫并不影响幼虫的发育时间,但可使幼虫化蛹时蜕皮受阻与羽化受到一定的抑制。     

“亚地克病”诊断标准探讨及修正建议

在新疆石河子市远郊缺碘地甲病区7～17岁儿童中取样,检测智力、精神运动功能、身高、体重和骨龄,发现精神运动发育障碍和骨龄落后的程度及发生频度明显高于非病区;而智力落后和体格发育落后两区无显著差异。根据这一发现认为在“亚地克病”诊断中,“精神运动发育测验”较“比内测验”更具有特异性和敏感性;建议在“出生、居住于缺碘地甲病区”前提下,将精神运动发育障碍和智力落后并列为主要条件。另根据地克病的分型原则,提出“亚地克病”的分型标准。     

Kindergarten children's representation and understanding of written number symbols

Two samples of kindergarten children's representation and understanding of written number symbols were examined in two time points in one academic year. About 85% of Chinese five year olds (mean = 5 years 10 months) were able to use conventional number symbols to represent the quantity of 30 or larger. At the end of the kindergarten year, 94% of Chinese six year olds (mean = 6 years 4 months) were able to use conventional number symbols to represent the quantity of 100 or larger. Some Chinese six year olds had problems in representing written addition and subtraction tasks. Children's ability to represent written number symbols, ability to represent written addition and subtraction formula and their performance on written addition and subtraction were closely related. The performance of children in a university-affiliated childcare center was better than that of the center serving working-class families in Time 1, but the performance reversed at the end of the kindergarten year.     

Estimated research and development costs of rotavirus vaccines

Diseases like rotavirus afflict both upper- and lower-income countries, but most serious illnesses and deaths occur among the latter. It is a vital public health issue that vaccines for these types of global diseases can recover research and development (R&D) costs from high-priced markets quickly so that manufacturers can offer affordable prices to lower-income nations. Cost recovery depends on how high R&D costs are, and this study attempts to replace high, unverified estimates with lower, more verifiable estimates for two new vaccines, RotaTeq (Merck) and Rotarix (GlaxoSmithKline or GSK), based on detailed searches of public information and follow-up interviews with senior informants. We also offer a new perspective on “cost of capital” as a claim for recovery from public bodies. Our estimates suggest that companies can recover all fixed costs quickly from affluent markets and thus can offer these vaccines to lower-income countries at prices they can afford. Better vaccines are a shared project between companies and public health agencies; greater transparency and consistency in reporting of R&D costs is needed so that fair prices can be established.